Target expression details
Target General Information | |||||
---|---|---|---|---|---|
Target ID | T02703 | ||||
Target Name | Nitric-oxide synthase inducible | ||||
Synonyms | HEP-NOS; Hepatocyte NOS; INOS; Inducible NOS; Inducible nitric oxide synthase; NOS, type II; NOS2 | ||||
Target Type | Clinical Trial | ||||
Gene Name | NOS2 | ||||
Biochemical Class | Oxidoreductases acting on paired donors | ||||
UniProt ID | NOS2_HUMAN | ||||
Target Gene Expression Profiles in the Disease-Relevant Drug Targeted Tissue of the Patients and Healthy Individuals | |||||
Disease | Osteoarthritis | ||||
Example drug | SD-6010 | Phase 3 | [1], [2] | ||
Tissue | Synovial tissue | ||||
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: -0.27 Z-score: -0.88 P-value: 4.24E-02 |
||||
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
![]() |
|||||
Disease | Asthma | ||||
Example drug | GW274150 | Phase 2 | [3], [2] | ||
Tissue | Nasal and bronchial airway | ||||
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: 0.74 Z-score: 0.70 P-value: 5.49E-08 |
||||
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
![]() |
|||||
Disease | Coronary artery disease | ||||
Example drug | LT-1951 | Phase 1/2 | [4], [2] | ||
Tissue | Peripheral blood | ||||
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: -0.02 Z-score: -0.09 P-value: 9.15E-01 |
||||
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
![]() |
|||||
Disease | Septic shock | ||||
Example drug | ONO-1714 | Discontinued in Phase 1 | [5], [2] | ||
Tissue | Whole blood | ||||
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: -0.07 Z-score: -0.26 P-value: 6.14E-01 |
||||
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
![]() |
|||||
Target Gene Expression Profiles in Other Tissues of Healthy Individuals | |||||
![]() |
|||||
Reference | |||||
REF 1 | ClinicalTrials.gov (NCT01438918) X-Ray Study Investigating The Safety And Efficacy Of SD-6010 In Subjects With Osteoarthritis Of The Knee. U.S. National Institutes of Health. | ||||
REF 2 | NCBI GEO: archive for functional genomics data sets--update. | ||||
REF 3 | ClinicalTrials.gov (NCT00370435) Study Of 90mg Of GW274150 In Subjects Over 50 Years, Who Have Rheumatoid Arthritis (RA). U.S. National Institutes of Health. | ||||
REF 4 | ClinicalTrials.gov (NCT00264706) PolyArginine Treated vEiN grafTs (PATENT). U.S. National Institutes of Health. | ||||
REF 5 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013758) |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.